Slack Davis Sanger Elevates John R. Davis To Partner; Youngest Partner in Firm’s History

Attorney John R. Davis has been promoted to Partner effective May 1, 2020. Based in the Austin office, Davis leads the firm’s class action and whistleblower litigation practice areas with a particular emphasis on consumer fraud, healthcare fraud, antitrust, environmental and insurance matters. He is the youngest attorney to be elected Partner in the firm’s 27-year history.

“John has established himself as a formidable litigator, handling high-profile class action and whistleblower matters,” said Managing Partner Mike Slack. “His relentless pursuit of justice for our clients makes him deserving of this promotion, and we’re excited to see him continue to grow the class action and whistleblower practice at the firm.”

Since joining the firm in 2016, Davis has spearheaded many notable cases, such as Grigson, et al. v. Farmers Group, Inc.where he played a leading role as court-appointed Class Counsel representing, with co-counsel, almost 800,000 auto insurance policyholders who were allegedly discriminated against by the company. The court recently granted preliminary approval for a $52 million settlement for the class, one of the largest settlements of its kind for a single state and one based on a novel theory of liability. Additionally, in February 2020, he obtained a $11.85 million False Claims Act settlement against pharmaceutical marketing company, Sanofi-Aventis U.S., LLC. The whistleblower lawsuit filed by Davis and co-counsel alleged that Sanofi was funneling kickbacks to patients disguised as donations to 501(c)(3) charitable organizations.

In another high-profile matter, Davis currently serves on the Plaintiffs’ Executive Committee in In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, MDL No. 2875 (D.N.J.), which began in 2018. The pharmaceutical recalls that triggered the litigation are the largest in U.S. history, and the litigation has shed light on shortcomings in generic pharmaceuticals imported to the U.S.

Read the full press release here.